Company Information for ALTIMMUNE UK LIMITED
CENTRAL SQUARE 5TH FLOOR, 29 WELLINGTON STREET, LEEDS, LS1 4DL,
|
Company Registration Number
02753142
Private Limited Company
Active |
Company Name | ||||
---|---|---|---|---|
ALTIMMUNE UK LIMITED | ||||
Legal Registered Office | ||||
CENTRAL SQUARE 5TH FLOOR 29 WELLINGTON STREET LEEDS LS1 4DL Other companies in NW1 | ||||
Previous Names | ||||
|
Company Number | 02753142 | |
---|---|---|
Company ID Number | 02753142 | |
Date formed | 1992-10-05 | |
Country | ENGLAND | |
Origin Country | United Kingdom | |
Type | Private Limited Company | |
CompanyStatus | Active | |
Lastest accounts | 31/12/2022 | |
Account next due | 30/09/2024 | |
Latest return | 18/06/2016 | |
Return next due | 16/07/2017 | |
Type of accounts | SMALL | |
VAT Number /Sales tax ID | GB850372536 |
Last Datalog update: | 2023-10-08 05:46:22 |
Companies House |
Menu
|
If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. Please DONATE to help. Alternatively by linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us. |
Officer | Role | Date Appointed |
---|---|---|
WILLIAM JAMES ENRIGHT |
Officer | Role | Date Appointed | Date Resigned |
---|---|---|---|
ELIZABETH ADKINS CZEREPAK |
Director | ||
CHRISTINE BRENNAN |
Director | ||
DAVID DRUTZ |
Director | ||
PHILIP LAWTON HODGES |
Director | ||
PHILIPPE JACQUES MICHEL POULETTY |
Director | ||
KLAUS OTTO SCHÄFER |
Director | ||
MARTEN STEEN |
Director | ||
FLORENT GROS |
Director | ||
BENJAMIN CHEN |
Director | ||
SANDY BLACKADDER PRIMROSE |
Director | ||
CARLTON BRADLEY BROWN |
Director | ||
JACOB UNO STANLEY GUNTERBERG |
Director | ||
KENNETH LESLIE POWELL |
Director | ||
DANIEL DRYSDALE ADAMS |
Director | ||
MARTIN JOSEPH BECKER |
Director | ||
BRENDA ELIZABETH REYNOLDS |
Director | ||
GUNNAR MAGNUS SEVERUS PERSSON |
Director | ||
GUNNAR MAGNUS SEVERUS PERSSON |
Director | ||
SANDRA WILLIAMS |
Company Secretary | ||
MICHAEL ANTHONY MCNAMARA |
Company Secretary | ||
DAVID HILL |
Director | ||
PHILIP JAMES HOLDEN SIZER |
Director | ||
CARLTON BRADLEY BROWN |
Company Secretary | ||
MICHAEL ANTHONY MCNAMARA |
Director | ||
DAVID HILL |
Director | ||
JOHN KARL SIMPSON |
Director | ||
WALTON LAW EDDLESTONE |
Company Secretary | ||
WATERLOW SECRETARIES LIMITED |
Nominated Secretary | ||
WATERLOW NOMINEES LIMITED |
Nominated Director |
Date | Document Type | Document Description |
---|---|---|
SMALL COMPANY ACCOUNTS MADE UP TO 31/12/22 | ||
Change of details for President Vipin Garg as a person with significant control on 2023-05-30 | ||
Director's details changed for President Vipin Garg on 2023-05-30 | ||
CONFIRMATION STATEMENT MADE ON 29/05/23, WITH NO UPDATES | ||
SMALL COMPANY ACCOUNTS MADE UP TO 31/12/21 | ||
AA | SMALL COMPANY ACCOUNTS MADE UP TO 31/12/21 | |
RP04PSC01 | Second filing of notification of person of significant controlVipin Garg | |
CS01 | CONFIRMATION STATEMENT MADE ON 29/05/22, WITH NO UPDATES | |
RP04AP01 | Second filing of director appointment of President Vipin Garg | |
RP04AP01 | Second filing of director appointment of President Vipin Garg | |
AA | SMALL COMPANY ACCOUNTS MADE UP TO 31/12/20 | |
CS01 | CONFIRMATION STATEMENT MADE ON 29/05/21, WITH NO UPDATES | |
PSC02 | Notification of Altimmune, Inc. as a person with significant control on 2021-05-13 | |
AA | GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/19 | |
CS01 | CONFIRMATION STATEMENT MADE ON 29/05/20, WITH NO UPDATES | |
AA | GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/18 | |
CS01 | CONFIRMATION STATEMENT MADE ON 29/05/19, WITH NO UPDATES | |
PSC01 | NOTIFICATION OF A PERSON WITH SIGNIFICANT CONTROL VIPIN GARG | |
AP01 | DIRECTOR APPOINTED VIPIN GARG | |
PSC07 | CESSATION OF WILLIAM JAMES ENRIGHT AS A PERSON OF SIGNIFICANT CONTROL | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR WILLIAM JAMES ENRIGHT | |
AD01 | REGISTERED OFFICE CHANGED ON 19/12/18 FROM London Bioscience Innovation Centre, 2 Royal College Street London NW1 0NH | |
AA | GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/17 | |
CS01 | CONFIRMATION STATEMENT MADE ON 12/06/18, WITH NO UPDATES | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR ELIZABETH ADKINS CZEREPAK | |
PSC07 | CESSATION OF ELIZABETH ADKINS CZEREPAK AS A PERSON OF SIGNIFICANT CONTROL | |
PSC01 | NOTIFICATION OF A PERSON WITH SIGNIFICANT CONTROL ELIZABETH ADKINS CZEREPAK | |
PSC01 | NOTIFICATION OF A PERSON WITH SIGNIFICANT CONTROL WILLIAM JAMES ENRIGHT | |
PSC01 | NOTIFICATION OF A PERSON WITH SIGNIFICANT CONTROL ELIZABETH ADKINS CZEREPAK | |
AP01 | DIRECTOR APPOINTED MRS. ELIZABETH ADKINS CZEREPAK | |
CS01 | CONFIRMATION STATEMENT MADE ON 18/06/17, WITH NO UPDATES | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR KLAUS SCHÄFER | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR PHILIPPE POULETTY | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR PHILIP HODGES | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR DAVID DRUTZ | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR MARTEN STEEN | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR CHRISTINE BRENNAN | |
AA | GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/16 | |
AA | FULL ACCOUNTS MADE UP TO 31/12/15 | |
AP01 | DIRECTOR APPOINTED DR. CHRISTINE BRENNAN | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR FLORENT GROS | |
LATEST SOC | 30/06/16 STATEMENT OF CAPITAL;GBP 39123.11 | |
AR01 | 18/06/16 ANNUAL RETURN FULL LIST | |
AA01 | Current accounting period extended from 30/11/15 TO 31/12/15 | |
RES15 | CHANGE OF NAME 26/08/2015 | |
CERTNM | Company name changed vaxin uk LIMITED\certificate issued on 01/09/15 | |
CONNOT | NOTICE OF CHANGE OF NAME NM01 - RESOLUTION | |
LATEST SOC | 20/07/15 STATEMENT OF CAPITAL;GBP 2092801.01 | |
AR01 | 18/06/15 ANNUAL RETURN FULL LIST | |
MEM/ARTS | ARTICLES OF ASSOCIATION | |
AA | FULL ACCOUNTS MADE UP TO 30/11/14 | |
RES01 | ADOPT ARTICLES 11/03/2015 | |
SH01 | 10/03/15 STATEMENT OF CAPITAL GBP 2092529.15 | |
SH08 | NOTICE OF NAME OR OTHER DESIGNATION OF CLASS OF SHARES | |
RES13 | COMPANY BUSINESS 13/02/2015 | |
RES01 | ALTER ARTICLES 13/02/2015 | |
AP01 | DIRECTOR APPOINTED DR KLAUS OTTO SCHÄFER | |
AP01 | DIRECTOR APPOINTED DR DAVID DRUTZ | |
AP01 | DIRECTOR APPOINTED MR WILLIAM JAMES ENRIGHT | |
AP01 | DIRECTOR APPOINTED MR PHILIP LAWTON HODGES | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR SANDY PRIMROSE | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR BENJAMIN CHEN | |
RES15 | CHANGE OF NAME 10/03/2015 | |
CERTNM | COMPANY NAME CHANGED IMMUNE TARGETING SYSTEMS (ITS) LIMITED CERTIFICATE ISSUED ON 11/03/15 | |
CONNOT | NOTICE OF CHANGE OF NAME NM01 - RESOLUTION | |
SH01 | 25/02/15 STATEMENT OF CAPITAL GBP 23173.18072 | |
RES12 | VARYING SHARE RIGHTS AND NAMES | |
SH01 | 30/11/14 STATEMENT OF CAPITAL GBP 23173.18 | |
RES11 | DISAPPLICATION OF PRE-EMPTION RIGHTS | |
LATEST SOC | 24/07/14 STATEMENT OF CAPITAL;GBP 172254.73 | |
AR01 | 18/06/14 CHANGES | |
SH01 | 28/03/14 STATEMENT OF CAPITAL GBP 172254.73 | |
AA | FULL ACCOUNTS MADE UP TO 30/11/13 | |
RES13 | COMPANY MAY MAKE AN OFFER OR AGREEMENT TO ALLOT SHARE OR GRANT RIGHTS 16/01/2014 | |
RES10 | AUTHORISED ALLOTMENT OF SHARES AND DEBENTURES | |
MEM/ARTS | ARTICLES OF ASSOCIATION | |
CC04 | STATEMENT OF COMPANY'S OBJECTS | |
RES01 | ALTER ARTICLES 04/07/2013 | |
AR01 | 18/06/13 FULL LIST | |
MISC | SECTION 519 | |
AA | FULL ACCOUNTS MADE UP TO 30/11/12 | |
AP01 | DIRECTOR APPOINTED DR BENJAMIN CHEN | |
RES13 | 7,0000000 FIXED RATE LOAN EQUAL WARRANTS 18/06/2012 | |
RES10 | AUTHORISED ALLOTMENT OF SHARES AND DEBENTURES | |
SH01 | 09/07/12 STATEMENT OF CAPITAL GBP 171885.87 | |
AR01 | 18/06/12 FULL LIST | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR CARLTON BROWN | |
MEM/ARTS | ARTICLES OF ASSOCIATION | |
RES12 | VARYING SHARE RIGHTS AND NAMES | |
RES01 | ALTER ARTICLES 26/04/2012 | |
AA | FULL ACCOUNTS MADE UP TO 30/11/11 | |
RES11 | DISAPPLICATION OF PRE-EMPTION RIGHTS | |
RES10 | AUTHORISED ALLOTMENT OF SHARES AND DEBENTURES | |
SH01 | 03/10/11 STATEMENT OF CAPITAL GBP 162844.67 | |
SH01 | 26/09/11 STATEMENT OF CAPITAL GBP 161725.70 | |
AR01 | 18/06/11 FULL LIST | |
AP01 | DIRECTOR APPOINTED DR MARTEN STEEN | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR JACOB GUNTERBERG | |
AA | FULL ACCOUNTS MADE UP TO 30/11/10 | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR KENNETH POWELL | |
SH01 | 10/11/10 STATEMENT OF CAPITAL GBP 125491.67 | |
AR01 | 23/08/10 FULL LIST | |
SH01 | 23/08/10 STATEMENT OF CAPITAL GBP 92574.76 | |
AA | FULL ACCOUNTS MADE UP TO 30/11/09 | |
AR01 | 18/06/10 FULL LIST | |
CH01 | DIRECTOR'S CHANGE OF PARTICULARS / DR SANDY BLACKADDER PRIMROSE / 18/06/2010 | |
CH01 | DIRECTOR'S CHANGE OF PARTICULARS / PHILIPPE JACQUES MICHEL POULETTY / 18/06/2010 | |
CH01 | DIRECTOR'S CHANGE OF PARTICULARS / FLORENT GROS / 18/06/2010 | |
CH01 | DIRECTOR'S CHANGE OF PARTICULARS / CARLTON BRADLEY BROWN / 18/06/2010 | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR DANIEL ADAMS | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR MARTIN BECKER | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR BRENDA REYNOLDS | |
RES10 | AUTHORISED ALLOTMENT OF SHARES AND DEBENTURES | |
RES01 | ALTER ARTICLES 09/02/2010 | |
RES01 | ADOPT ARTICLES 09/02/2010 | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR GUNNAR PERSSON | |
AP01 | DIRECTOR APPOINTED MR JACOB UNO STANLEY GUNTERBERG | |
RES01 | ALTER ARTICLES 22/09/2009 | |
MEM/ARTS | ARTICLES OF ASSOCIATION | |
AP01 | DIRECTOR APPOINTED GUNNAR MAGNUS SEVERUS PERSSON | |
AP01 | DIRECTOR APPOINTED DR KENNETH POWELL | |
TM01 | APPOINTMENT TERMINATED, DIRECTOR GUNNAR PERSSON | |
288b | APPOINTMENT TERMINATED SECRETARY SANDRA WILLIAMS | |
363a | RETURN MADE UP TO 18/06/09; FULL LIST OF MEMBERS | |
AA | FULL ACCOUNTS MADE UP TO 30/11/08 | |
288c | DIRECTOR'S CHANGE OF PARTICULARS / CARLTON BROWN / 30/11/2008 | |
288b | APPOINTMENT TERMINATED SECRETARY MICHAEL MCNAMARA | |
288a | SECRETARY APPOINTED SANDRA WILLIAMS | |
288a | DIRECTOR APPOINTED BRENDA ELIZABETH REYNOLDS | |
363a | RETURN MADE UP TO 05/10/08; FULL LIST OF MEMBERS | |
123 | NC INC ALREADY ADJUSTED 30/06/08 | |
RES01 | ADOPT MEM AND ARTS 30/06/2008 | |
RES04 | GBP NC 100000/200000 30/06/2008 | |
AA | ACCOUNTS FOR 'SMALL' CO. MADE UP TO 30/11/07 | |
288a | DIRECTOR APPOINTED DR SANDY BLACKADDER PRIMROSE | |
363s | RETURN MADE UP TO 05/10/07; CHANGE OF MEMBERS | |
AA | TOTAL EXEMPTION SMALL ACCOUNTS MADE UP TO 30/11/06 | |
SA | SHARES AGREEMENT OTC |
Total # Mortgages/Charges | 0 |
---|---|
Mortgages/Charges outstanding | 0 |
Mortgages Partially Satisifed | 0 |
Mortgages Satisfied/Paid | 0 |
Average | Max | |
MortgagesNumMortCharges | 0.33 | 8 |
MortgagesNumMortOutstanding | 0.17 | 8 |
MortgagesNumMortPartSatisfied | 0.00 | 1 |
MortgagesNumMortSatisfied | 0.16 | 8 |
This shows the max and average number of mortgages for companies with the same SIC code of 72110 - Research and experimental development on biotechnology
The top companies supplying to UK government with the same SIC code (72110 - Research and experimental development on biotechnology) as ALTIMMUNE UK LIMITED are:
Origin | Destination | Date | Import Code | Imported Goods classification description |
---|---|---|---|---|
29371900 | Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts) | |||
29371200 | Insulin and its salts, used primarily as hormones | |||
29379000 | Hormones, natural or reproduced by synthesis; derivatives and structural analogues thereof, used primarily as hormones (excl. polypeptide hormones, protein hormones, glycoprotein hormones, steroidal hormones, catecholamine hormones, prostaglandins, thromboxanes and leukotrienes, their derivatives and structural analogues, and amino-acid derivatives, and products of 3002 10) | |||
29379000 | Hormones, natural or reproduced by synthesis; derivatives and structural analogues thereof, used primarily as hormones (excl. polypeptide hormones, protein hormones, glycoprotein hormones, steroidal hormones, catecholamine hormones, prostaglandins, thromboxanes and leukotrienes, their derivatives and structural analogues, and amino-acid derivatives, and products of 3002 10) | |||
30029090 | Toxins and similar products, e.g. plasmodia (excl. vaccines and cultures of micro-organisms) | |||
29371900 | Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts) | |||
29379000 | Hormones, natural or reproduced by synthesis; derivatives and structural analogues thereof, used primarily as hormones (excl. polypeptide hormones, protein hormones, glycoprotein hormones, steroidal hormones, catecholamine hormones, prostaglandins, thromboxanes and leukotrienes, their derivatives and structural analogues, and amino-acid derivatives, and products of 3002 10) | |||
29420000 | Separate chemically defined organic compounds, n.e.s. | |||
35040090 | Peptones and their derivatives; other albuminous substances and their derivatives, n.e.s.; hide powder, whether or not chromed (excl. concentrated milk proteins with a protein content > 85 % by weight, calculated on the dry matter | |||
30021091 | Haemoglobin, blood globulins and serum globulins | |||
29379000 | Hormones, natural or reproduced by synthesis; derivatives and structural analogues thereof, used primarily as hormones (excl. polypeptide hormones, protein hormones, glycoprotein hormones, steroidal hormones, catecholamine hormones, prostaglandins, thromboxanes and leukotrienes, their derivatives and structural analogues, and amino-acid derivatives, and products of 3002 10) | |||
30029010 | Human blood | |||
30049000 | Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic purposes, put up in measured doses "incl. those in the form of transdermal administration" or in forms or packings for retail sale (excl. medicaments containing antibiotics, medicaments containing hormones or steroids used as hormones, but not containing antibiotics, medicaments containing alkaloids or derivatives thereof but not containing hormones or antibiotics and medicaments containing provitamins, vitamins | |||
29224985 | Amino-acids and their esters; salts thereof (excl. those containing > one kind of oxygen function, lysine and its esters, and salts thereof, and glutamic acid, anthranilic acid, tilidine "INN" and their salts and beta-alanine) | |||
30021010 | Antisera | |||
38220000 | Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products) | |||
30029090 | Toxins and similar products, e.g. plasmodia (excl. vaccines and cultures of micro-organisms) | |||
29379000 | Hormones, natural or reproduced by synthesis; derivatives and structural analogues thereof, used primarily as hormones (excl. polypeptide hormones, protein hormones, glycoprotein hormones, steroidal hormones, catecholamine hormones, prostaglandins, thromboxanes and leukotrienes, their derivatives and structural analogues, and amino-acid derivatives, and products of 3002 10) | |||
30029090 | Toxins and similar products, e.g. plasmodia (excl. vaccines and cultures of micro-organisms) | |||
29349960 | Chlorprothixene (INN); thenalidine (INN) and its tartrates and maleates; furazolidone (INN); 7-aminocephalosporanic acid; salts and esters of (6R,7R)-3-acetoxymethyl-7-[(R)-2-formyloxy-2-phenylacetamido]-8- oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 1-[2-(1,3-Dioxan-2-yl)ethyl]-2-methylpyridinium bromide | |||
30021095 | ||||
35040090 | Peptones and their derivatives; other albuminous substances and their derivatives, n.e.s.; hide powder, whether or not chromed (excl. concentrated milk proteins with a protein content > 85 % by weight, calculated on the dry matter | |||
29029000 | Cyclic hydrocarbons (excl. cyclanes, cyclenes, benzene, toluene, xylenes, styrene, ethylbenzene and cumene) | |||
29224985 | Amino-acids and their esters; salts thereof (excl. those containing > one kind of oxygen function, lysine and its esters, and salts thereof, and glutamic acid, anthranilic acid, tilidine "INN" and their salts and beta-alanine) | |||
29379000 | Hormones, natural or reproduced by synthesis; derivatives and structural analogues thereof, used primarily as hormones (excl. polypeptide hormones, protein hormones, glycoprotein hormones, steroidal hormones, catecholamine hormones, prostaglandins, thromboxanes and leukotrienes, their derivatives and structural analogues, and amino-acid derivatives, and products of 3002 10) | |||
29371900 | Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts) | |||
38220000 | Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products) | |||
35040090 | Peptones and their derivatives; other albuminous substances and their derivatives, n.e.s.; hide powder, whether or not chromed (excl. concentrated milk proteins with a protein content > 85 % by weight, calculated on the dry matter | |||
38220000 | Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products) | |||
37 | ||||
38220000 | Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products) | |||
30049000 | Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic purposes, put up in measured doses "incl. those in the form of transdermal administration" or in forms or packings for retail sale (excl. medicaments containing antibiotics, medicaments containing hormones or steroids used as hormones, but not containing antibiotics, medicaments containing alkaloids or derivatives thereof but not containing hormones or antibiotics and medicaments containing provitamins, vitamins | |||
30021091 | Haemoglobin, blood globulins and serum globulins | |||
29420000 | Separate chemically defined organic compounds, n.e.s. | |||
29420000 | Separate chemically defined organic compounds, n.e.s. | |||
29012900 | Hydrocarbons, acyclic, unsaturated (excl. ethylene, propene "propylene", butene "butylene" and isomers thereof and Buta-1,3-diene and isoprene) | |||
30021099 | ||||
29420000 | Separate chemically defined organic compounds, n.e.s. | |||
28261910 | Fluorides of ammonium or of sodium | |||
29420000 | Separate chemically defined organic compounds, n.e.s. | |||
29225000 | Amino-alcohol-phenols, amino-acid-phenols and other amino-compounds with oxygen function (excl. amino-alcohols, amino-naphthols and other amino-phenols, their ethers and esters and salts thereof, amino-aldehydes, amino-ketones and amino-quinones, and salts thereof, amino-acids and their esters and salts thereof) | |||
30021095 | ||||
29224985 | Amino-acids and their esters; salts thereof (excl. those containing > one kind of oxygen function, lysine and its esters, and salts thereof, and glutamic acid, anthranilic acid, tilidine "INN" and their salts and beta-alanine) | |||
28070010 | ||||
29224985 | Amino-acids and their esters; salts thereof (excl. those containing > one kind of oxygen function, lysine and its esters, and salts thereof, and glutamic acid, anthranilic acid, tilidine "INN" and their salts and beta-alanine) | |||
30021095 | ||||
28061000 | Hydrogen chloride "hydrochloric acid" | |||
38220000 | Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products) | |||
38220000 | Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products) | |||
29371900 | Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts) | |||
83099090 | Stoppers, caps and lids, incl. screw caps and pouring stoppers, capsules for bottles, threaded bungs, bung covers, seals and other packing accessories, of base metal (excl. crown corks, capsules of lead and capsules of aluminium of a diameter > 21 mm) |
For goods imported into the United Kingdom, only imports originating from outside the EU are shown
Category | Award/Grant | |
---|---|---|
Pre-Clinical Development of a Novel Therapeutic Vaccine for Chronic Hepatitis B : Feasibility Study | 2013-04-01 | £ 2,025,095 |
Feasibility assessment of a novel vaccine platform for the stratified therapeutic vaccine intervention in non-small cell lung cancer. : Feasibility Study | 2013-03-01 | £ 150,000 |
How is this useful? The company may be investing in new products to generate new revenue streams or investing in new technologies to increase productivity / reduce costs. The company may own IPR as a result.
If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. Please DONATE to help. Alternatively by linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us. |